Johnson & Johnson, BMS fight US drug price plan at Third Circuit

16 July 2024 - Pharmaceutical giants Johnson & Johnson, BMS and AstraZeneca are rejecting federal district court decisions that rule ...

Read more →

Full-Life Technologies granted FDA fast track designation for 225Ac-FL-020 for the treatment of metastatic castration resistant prostate cancer

2 July 2024 - Full-Life Technologies today announced that the US FDA has granted fast track designation for 225Ac-FL-020, the company's ...

Read more →

Health Canada authorises Rybrevant (amivantamab) in combination with carboplatin and pemetrexed as the only targeted first-line treatment approved for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations

3 July 2024 - Phase 3 PAPILLON study showed Rybrevant in combination with carboplatin and pemetrexed significantly improved progression-free survival, ...

Read more →

HAS clarifies the framework of the “bet” on early access to medicines

24 June 2024 - Committed to a process of continuous development of its methods, the High Authority of Health is launching ...

Read more →

Gadopiclenol as an MRI contrast agent: first benefit assessment of a diagnostic agent

1 July 2024 - For the first time, IQWiG has evaluated a drug that is a diagnostic agent within the ...

Read more →

President Biden: Novo Nordisk, Eli Lilly must stop ripping off Americans with high drug prices

2 July 2024 - If Novo Nordisk and other pharmaceutical companies refuse to substantially lower prescription drug prices in our country ...

Read more →

Formulary coverage of brand name adalimumab and biosimilars across Medicare Part D plans

2 July 2024 - Adalimumab (Humira) is a top-selling drug in Medicare Part D, representing $4.7 billion of Medicare spending in ...

Read more →

China’s National Medical Products Administration Approves Xtandi (enzalutamide) in metastatic hormone sensitive prostate cancer

2 July 2024 - Approval marks Xtandi’s third indication for advanced prostate cancer in China. ...

Read more →

Johnson & Johnson receives approval from US FDA and European Commission for Sirturo (bedaquiline)

2 July 2024 - Johnson & Johnson announced today that the US FDA has issued traditional approval for Sirturo (bedaquiline) ...

Read more →

CSL Behring’s haemophilia B drug Idelvion gets insurance coverage

2 July 2024 - CSL Behring's long-acting hemophilia B treatment Idelvion (albutrepenonacog alfa) has come to receive reimbursement in Korea. ...

Read more →

Inozyme Pharma announces FDA fast track designation for INZ-701 in ABCC6 deficiency

2 July 2024 - Inozyme Pharma today announced that the US FDA has granted fast track designation to INZ-701 for ...

Read more →

Approval of newest Alzheimer’s drug will accelerate new era of treatment

2 July 2024 - With the arrival of Lilly’s Kisunla, Alzheimer’s care could become more like treatment of cancer and rheumatoid ...

Read more →

Osimertinib mesylate for the adjuvant treatment of patients with EGFR mutation positive non-small-cell lung cancer after complete tumour resection

27 June 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...

Read more →

Kye Pharmaceuticals announces the availability of Quillivant ER chewable tablets for the treatment of children with ADHD

2 July 2024 - Quillivant ER chewable tablets are the first and only extended release chewable methylphenidate tablets approved in Canada. ...

Read more →

Dupixent (dupilumab) approved in the European Union as the first ever targeted therapy for patients with COPD

3 July 2024 - First in world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on ...

Read more →

Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout

2 July 2024 - Sobi today announced the initiation of a rolling biologics license application to the US FDA for SEL-212.  ...

Read more →